Last reviewed · How we verify

Oral Albuterol Extended Release

VA Office of Research and Development · FDA-approved active Small molecule Quality 0/100

Oral Albuterol Extended Release is a Small molecule drug developed by VA Office of Research and Development. It is currently FDA-approved. Also known as: VoSpire.

At a glance

Generic nameOral Albuterol Extended Release
Also known asVoSpire
SponsorVA Office of Research and Development
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Oral Albuterol Extended Release

What is Oral Albuterol Extended Release?

Oral Albuterol Extended Release is a Small molecule drug developed by VA Office of Research and Development.

Who makes Oral Albuterol Extended Release?

Oral Albuterol Extended Release is developed and marketed by VA Office of Research and Development (see full VA Office of Research and Development pipeline at /company/va-office-of-research-and-development).

Is Oral Albuterol Extended Release also known as anything else?

Oral Albuterol Extended Release is also known as VoSpire.

What development phase is Oral Albuterol Extended Release in?

Oral Albuterol Extended Release is FDA-approved (marketed).

Related